Research programme: B-Raf kinase inhibitors - Eli Lilly/Deciphera Pharmaceuticals

Drug Profile

Research programme: B-Raf kinase inhibitors - Eli Lilly/Deciphera Pharmaceuticals

Latest Information Update: 07 Feb 2014

Price : $50

At a glance

  • Originator Deciphera Pharmaceuticals
  • Developer Deciphera Pharmaceuticals; Eli Lilly
  • Class Small molecules
  • Mechanism of Action Proto oncogene protein b raf inhibitors; Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Malignant melanoma

Most Recent Events

  • 01 Feb 2012 DP 4978 entered phase I trials for Cancer in the USA
  • 17 Jan 2011 Preclinical trials in Malignant melanoma in USA (unspecified route)
  • 03 Oct 2008 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top